This review examines the relationship between testosterone deficiency syndrome (TDS), its treatment, and the associated risks of prostate and breast cancer. TDS is prevalent in aging men and linked to conditions such as sexual dysfunction, metabolic syndrome, and diabetes. The study found that restoring testosterone levels through testosterone replacement therapy
This systematic review and meta-analysis examined urinary 8-hydroxy-2-deoxyguanosine (8-OHdG) as a biomarker for oxidative DNA damage, analyzing 84 studies with 128 subgroups. The study found a pooled geometric mean of 3.9 ng/mg creatinine for urinary 8-OHdG levels in healthy adults with a mean BMI ≤ 25, measured using chemical methods.
This cohort study evaluated the breast cancer risks associated with menopausal hormone replacement therapy (HRT) in postmenopausal women, comparing estrogen-only therapy to estrogen-progestin therapy. The study found that both estrogen-only and estrogen-progestin therapies increased breast cancer risk, with estrogen-progestin therapy showing a higher risk, particularly in women with lower BMI.
This study examines the impact of different progestagens in hormone replacement therapy (HRT) on breast cancer risk among postmenopausal women. Published in Gynecological Endocrinology (2009), it discusses how various progestins may influence breast cancer cell behavior differently, with some evidence suggesting that certain progestins could enhance the proliferation and invasiveness
This cohort study from the Million Women Study found that current hormone replacement therapy (HRT) use is linked to an increased risk of both incident and fatal breast cancer, with the risk being particularly higher for estrogen-progestagen combinations. The risk rises with the duration of use but decreases after cessation
